Viscous Gel for Localized Sinus Drug Delivery

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for chronic sinusitis face challenges in delivering medications to the sinuses in effective concentrations without causing side effects, as oral and intravenous therapies often result in drug distribution to the entire body, leading to tissue and organ toxicities, and other methods like nasal sprays, nebulization, and irrigations suffer from inefficiency and discomfort.

Innovation Solution

A viscous topical composition, such as a medicated gel with a viscosity suitable for maintaining presence within the sinus cavity, containing antimicrobial, anti-inflammatory, or other medications, applied directly through the nasal cavity using a syringe or catheter, which bypasses systemic drug concentration requirements and reduces medication waste.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If oral or intravenous medication is administered to treat chronic sinusitis, then the medication can reach the sinus cavity, but the drug distributes throughout the body causing tissue and organ toxicities

Engineering Contradiction:
Improvedrug concentration in sinusesVSAvoidsystemic side effects
Core Design Contradiction:
Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by transforming the medication into a viscous gel formulation that remains localized within the sinus cavity. The gel's high viscosity prevents systemic absorption while maintaining high local drug concentration at the infection site, thereby treating the sinusitis without distributing the drug throughout the body to cause organ toxicities.

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The viscous gel acts as an intermediary carrier that enables localized drug delivery. This gel medium allows the medication to be retained in the sinus cavity for extended periods, providing sustained local therapy while preventing the drug from entering the bloodstream and causing systemic side effects.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Ease of operation

If nasal sprays are used to deliver medication to the sinuses, then the treatment is non-invasive, but the large particle size prevents penetration into the sinuses

Engineering Contradiction:
Improvenon-invasive administrationVSAvoidparticle penetration capability
Core Design Contradiction:
Ease of operationVSVolume of moving object

Solution Approach 1:

The patent changes the physical parameter of the medication from a sprayable liquid with large particles to a viscous gel formulation. This parameter change allows the medication to be administered non-invasively through the nasal cavity while the gel's rheological properties enable it to flow into and penetrate the sinus cavities effectively, overcoming the particle size limitation of nasal sprays.

Inventive Principle:
Principle #35Parameter changes

3Quantity of substance

If sinus irrigations are performed to deliver medication, then the sinus cavity can be flushed, but up to 97% of the medicated irrigation is wasted rushing out of the sinuses

Engineering Contradiction:
Improvemedication deliveryVSAvoidmedication waste
Core Design Contradiction:
Quantity of substanceVSLoss of substance

Solution Approach 1:

The patent changes the physical state of the medication from a low-viscosity irrigation solution to a high-viscosity gel. This parameter change in viscosity prevents the medication from rapidly flowing out of the sinus cavity, reducing medication waste from 97% to minimal levels, while still allowing effective delivery of the active drug substance to the infection site.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The gel formulation provides excessive retention of medication within the sinus cavity, ensuring that the medication remains in place long enough to be effective even if some irrigation fluid is lost. This excessive retention approach guarantees adequate drug exposure time and reduces the need for repeated administrations.

Inventive Principle:
Principle #16Partial or excessive action

4Quantity of substance

If intravenous drug administration is used to treat sinusitis, then the medication can be delivered systemically, but the cost ranges from $2,500 to $21,000 and requires monitoring of serum drug concentrations

Engineering Contradiction:
Improvedrug deliveryVSAvoidtreatment complexity
Core Design Contradiction:
Quantity of substanceVSDevice complexity

Solution Approach 1:

The patent extracts the medication delivery from the complex systemic intravenous administration pathway and delivers it directly to the sinus cavity via nasal administration. This eliminates the need for intravenous access, serum concentration monitoring, and hospital-based infusion equipment, significantly reducing treatment complexity while maintaining effective drug delivery to the target site.

Inventive Principle:
Principle #2Taking out (Extraction)

Data Source

PatentUS8916171B2Topical delivery of viscous medications for the treatment of diseases associated with chronic sinusitis
Publication Date: 2014.12.23 TOPICAL SINUS THERAPEUTICS

AI summary

A medication or combination of medications for the treatment of a disease involving the sinuses is incorporated into a sterile medical gel. The viscosity of the gel or the adhesion of the gel to the patient's sinus cavity allows the gel to be maintained in the cavity for a sufficient length of time for treatment of the affected area. This reduces the amount of wasted medication that would otherwise result from other topical methods.